Retail Investors Remain Cautious After Anika’s Q3 Earnings Misses Estimates
Barrington analyst Michael Petusky has cut the firm’s price target to $25 from $37 Shares of Anika Therapeutics ($ANIK), which provides early intervention for orthopedic care, slipped 3.39% on Friday,…